Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?

Bibliography

• WILT TJ, BLOOMFIELD HE, MACDONALD R et al.: Effectiveness of statin therapy in adults with coronary heart disease. Arch. Intern. Med. (2004)164:1427-1436.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P, CROWE T, SASIELA WJ, TSAI J et al.: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERsaL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. (2005) 352:29-38.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, NICHOLLS SJ, SIPAHI I et al.; ASTEROID INVESTIGATORS: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 295:1556-1565
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl. J. Med. (2004) 350:1495-1504.
   PubMed Web of Science ®Google Scholar
• LAROSA JC, GRUNDY SM, WATERS DD et al.: Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl. J. Med. (2005) 352:1425-1435.
   PubMed Web of Science ®Google Scholar
• MERTEN M, DONG JF, LOPEZ JA, THIAGARAJAN P: Cholesterol sulfate: a new adhesive molecule for platelets. Circulation (2001) 103:2032-2034
   PubMed Web of Science ®Google Scholar
• NOTARBARTOLO A, DAVI G, AVERNA M et al.: Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. (1995) 15:247-251
   PubMed Web of Science ®Google Scholar
• LACOSTE L, LAM JY, HUNG J, LETCHACOVSKI G, SOLYMOSS CB, WATERS D: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation (1995) 92:3172-3177
   PubMed Web of Science ®Google Scholar
• DUPUIS J, TARDIF JC, CERNACEK P, THEROUX P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation (1999) 99:3227-3233.
   PubMed Web of Science ®Google Scholar
• ENAS EA. Coronary artery disease epidemic in Indians: a cause for alarm and call for action. J. Indian Med. Assoc. (2000) 98:694-5, 697-702.
   PubMedGoogle Scholar
• HUGHES LO, RAVAL U, RAFTERY EB: First myocardial infarctions in Asian and white men. BMJ (1989) 298:1345-1350.
   PubMedGoogle Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA (1998) 279:1615-1622.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl. J. Med. (1995) 333:1301-1307.
   PubMed Web of Science ®Google Scholar
• BANDYOPADHYAY S, BAYER AJ, O'MAHONY MS: Age and gender bias in statin trials. QJM (2001) 94:127-132.
   PubMed Web of Science ®Google Scholar
• BIOLETTO S, GOLAY A, MUNGER R, KALIX B, JAMES RW: Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects. Am. J. Clin. Nutr. (2000) 71:443-449.
   PubMed Web of Science ®Google Scholar
• GUERIN M, LE GOFF W, LASSEL TS, VAN TOL A, STEINER G, CHAPMAN MJ: Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler. Thromb. Vasc. Biol. (2001) 21:282-288.
   PubMed Web of Science ®Google Scholar
• VERSCHUREN WM, JACOBS DR, BLOEMBERG BP et al.: Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five year followup of the seven countries study. JAMA (1995) 274:131-136.
   PubMed Web of Science ®Google Scholar
• COLLINS R, ARMITAGE J, PARISH S, SLEIGH P, PETO R; HEART PROTECTION STUDY COLLABORATIVE GROUP.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet (2003) 361:2005-2016.
   PubMed Web of Science ®Google Scholar
• COLHOUN HM, BETTERIDGE DJ, DURRINGTON PN et al.: CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet (2004) 364:685-696.
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet (1994) 344:1383-1389.
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention With Pravastatin In Ischemic Disease (LIPID) Study Group. N. Engl. J. Med. (1998) 339:1349-1357
   Google Scholar
• SEVER PS, DHALOF B, POULTER NR et al.: ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet (2003) 361:1149-1158.
   PubMed Web of Science ®Google Scholar
• NISSEN SE, TUZCU EM, SCHOENHAGEN P et al.:: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERsaL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. (2005) 352:29-38.
   PubMed Web of Science ®Google Scholar
• MULDER HJ, BAL ET, JUKEMA JW et al.: Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am. J. Cardiol. (2000) 86:742-746.
   PubMed Web of Science ®Google Scholar
• DHAWAN J, BRAY CL. Angiographic comparison of coronary artery disease between Asians and Caucasians. Postgrad. Med. J. (1994) 70:625-630.
   PubMed Web of Science ®Google Scholar
• CANNON CP, BRAUNWALD E, MCCABE CH et al.: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. (2004) 350:1495-1504.
   PubMed Web of Science ®Google Scholar
• DE LEMOS JA, BLAZING MA, WIVIOTT SD et al.: A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. (2004) 292:1307-1316.
   PubMed Web of Science ®Google Scholar
• LOWRY PJ, LAMB P, WATSON RD et al.: Influence of racial origin on admission rates of patients with suspected myocardial infarction in Birmingham. Br. Heart J. (1991) 66:29-35.
   PubMedGoogle Scholar
• WILKINSON P, SAYER J, LAJI K et al.: Comparison of case fatality in South Asian and white patients after acute myocardial infarction: observational study. BMJ (1996) 312:1330-1333.
   PubMedGoogle Scholar
• SHAUKAT N, DE BONO DP, CRUICKSHANK JK: Clinical features, risk factors, and referral delay in British patients of Indian and European origin with angina matched for age and extent of coronary atheroma. BMJ (1993) 307:717-718.
   PubMedGoogle Scholar
• ARONOW HD, QUINN MJ, GURM HS: Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipid-lowering therapy. J. Am. Coll. Cardiol. (2002) 39:32A
   Google Scholar
• MOSCUCCI M, KLINE-ROGERS E, SHARE D et al., FOR THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM (BMC2): Effect of pre-procedure lipid lowering therapy on inhospital mortality following percutaneous coronary interventions: an analysis of a large multicenter database. J. Am. Coll. Cardiol. (2002) 39:32A
   Google Scholar
• FEDER G, CROOK AM, MAGEE P, BANERJEE S, TIMMIS AD, HEMINGWAY H: Ethnic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography. BMJ (2002) 324:511-516.
   PubMed Web of Science ®Google Scholar
• HEMINGWAY H, CROOK AM, FEDER G et al.: Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl. J. Med. (2001) 344:645-654.
   PubMed Web of Science ®Google Scholar
• GOLDSMITH I, LIP GY, TSANG G, PATEL RL: Comparison of primary coronary artery bypass surgery in a British South-Asian and white Caucasian population. Eur. Heart J. (1999) 20:1094-1100.
   PubMed Web of Science ®Google Scholar
• SCHÖNBECK U, LIBBY P: Inflammation, immunity, and HMG-CoA reductase inhibitors. Statins as antiinflammatory agents? Circulation (2004) 109:II-18 –II26.
   PubMedGoogle Scholar
• YAMASHITA H, SHIMADA K, SEKI E, MOKUNO H, DAIDA H: Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am. J. Cardiol. (2003) 91:133-136.
   PubMed Web of Science ®Google Scholar
• CHAMBERS JC, EDA S, BASSETT P et al.: C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 104:145-150.
   PubMed Web of Science ®Google Scholar
• LOW AF, SEOW SC, YEOH KG, LIM YT, TAN HC, YEO TC: High-sensitivity C-reactive protein is predictive of medium-term cardiac outcome in high-risk Asian patients presenting with chest pain syndrome without myocardial infarction. Ann. Acad. Med. Singapore (2004) 33:407-412.
   PubMed Web of Science ®Google Scholar
• MUSIAL J, UNDAS A, GAJEWSKI P, JANKOWSKI M, SYDOR W, SZCZEKLIK A: Antiinflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol. (2001) 77:247-253.
   PubMed Web of Science ®Google Scholar
• MORA S, RIDKER PM: Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol. (2006) 97:33-41.
   PubMed Web of Science ®Google Scholar
• LUSCHER TF, BARTON M. Biology of the endothelium. Clin. Cardiol. (1997) 20:3-10.
   PubMed Web of Science ®Google Scholar
• FICHTLSCHERER S, ROSENBERGER G, WALTER DH BREUER S, DIMMELER S, ZEIHER AM: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation (2000) 102:1000-1006.
   PubMed Web of Science ®Google Scholar
• JOHN S, SCHLAICH M, LANGENFELD M, SCHMITZ G, WEIDINGER G, SCHMIEDER RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation (1998) 98:211-216.
   PubMed Web of Science ®Google Scholar
• SCHACHINGER V, BRITTEN MB, ELSNER M, WALTER DH, SCHARRER I, ZEIHER AM: A positive family history of premature coronary artery disease is associated with impaired endothelium- dependent coronary blood flow regulation. Circulation (1999) 100:1502-1508.
   PubMed Web of Science ®Google Scholar
• VITA JA, TREASURE CB, NABEL EG et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation (1990) 81:491-497.
   PubMed Web of Science ®Google Scholar
• CHAMBERS JC, MCGREGOR A, JEAN-MARIE J, KOONER J: Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians. Heart (1999) 81:501-504.
   PubMed Web of Science ®Google Scholar
• DIN JN, ASHMAN OA, AFTAB SM, JUBB AW, NEWBY DE, FLAPAN AD: Increased arterial stiffness in healthy young South Asian men. J. Hum. Hypertens. (2006) 20:163-165
   PubMed Web of Science ®Google Scholar
• ENDRES M, LAUFS U: Effects of statins on endothelium and signaling mechanisms. Stroke (2004) 35:2708-2711.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, TARDIF JC, ROULEAU JL et al.: Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial). Am. J. Cardiol. (2005) 96:1207-1213.
   PubMed Web of Science ®Google Scholar
• TSIARA S, ELISAF M, MIKHAILIDIS DP: Early vascular benefits of statin therapy. Curr. Med. Res. Opin. (2003) 19:540-556.
   PubMed Web of Science ®Google Scholar
• TAN CE, LOH LM, TAI ES: Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med J. (2003) 44:635-638.
   PubMedGoogle Scholar
• JAYARAM S, JAIN MM, NAIKAWADI AA, GAWDE A, DESAI A: Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study. J. Indian Med. Assoc. (2004) 102:48-50.
   PubMedGoogle Scholar
• POULTER NR, CAULFIELD M, FEDER G; ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL: Ethnic variations in response to a statin (EVIREST). J. Hum. Hypertens. (2001) 15:S87-S89.
   Google Scholar
• NISSEN SE: High-dose statins in acute coronary syndromes: not just lipid levels. JAMA (2004) 292:1365-1367
   PubMed Web of Science ®Google Scholar
• GRAHAM DJ, STAFFA JA, SHATIN D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. (2004) 292:2585-2590.
   PubMed Web of Science ®Google Scholar
• LEE E, RYAN S, BIRMINGHAM B, ZALIKOWSKI J et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. (2005) 78:330-341.
   PubMed Web of Science ®Google Scholar
• ALSHEIKH-ALI AA, AMBROSE MS, KUVIN JT, KARAS RH: The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation (2005) 111:3051-3057.
   PubMed Web of Science ®Google Scholar
• FDA CONSUMER MAGAZINE: New warning for statin drug. (2005) 39(3):2.
   Google Scholar
• FISCHBACHER CM, HUNT S, ALEXANDER L: How physically active are Indo Asians in the United Kingdom? A literature review. J Public Health (Oxf). (2004) 26:250-258.
   PubMed Web of Science ®Google Scholar
• DHAWAN J, BRAY CL: Asian Indians, coronary artery disease, and physical exercise. Heart (1997) 78:550-554.
   PubMed Web of Science ®Google Scholar
• DHINGRA V, CHATTERJEE A, GULERIA R et al.: Adverse physical activity pattern in urban adolescents. J. Assoc. Phys. India (2003)50:1521
   Google Scholar
• SIMMONS D, WILLIAMS R: Dietary practices among Europeans and different South Asian groups in Coventry. Br. J. Nutr. (1997) 78:85
   Google Scholar
• BRITISH NUTRITION FOUNDATIONTASK FORCE: Repeat on unsaturated fatty acids. Chapman and Hall, London (1992).
   Google Scholar
• MANAV M, SU J, HUGHES K, LEE HP, ONG CN: Omega-3 fatty acids and selenium as coronary heart disease risk modifying factors in Asian Indian and Chinese males. Nutrition (2004) 20:967-973.
   PubMed Web of Science ®Google Scholar
• BHOPAL R, UNWIN N, WHITE M et al.: Heterogeneity of coronary heart disease risk factors in Indian, Pakistani,Bangladeshi, and European origin populations: cross sectional study. BMJ (1999) 319:215-220.
   PubMed Web of Science ®Google Scholar
• MCKEIGUE PM, MARMOT MG, ADELSTEIN AM et al.: Diet and risk factors for coronary heart disease in Asians in northwest London. Lancet (1985) 2:1086-1090.
   PubMed Web of Science ®Google Scholar
• JHA P, ENAS E, YUSUF S: Coronary Artery Disease in Asian Indians: Prevalence and Risk Factors. Asian Am. Pac. Isl. J. Health (1993) 1:163-175.
   PubMedGoogle Scholar
• MILLER GJ, BECKLES GL, ALEXIS SD, BYAM NT, PRICE SG: Serum lipoproteins and susceptibility of men of Indian descent to coronary heart disease. The St James Survey, Trinidad. Lancet (1982) 2:200-203.
   PubMed Web of Science ®Google Scholar
• LEE J, HENG D, CHIA KS, CHEW SK et al.: Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study. Int. J. Epidemiol. (2001) 30:983-988.
   PubMed Web of Science ®Google Scholar
• HOKANSON JE, AUSTIN MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk (1996) 3:213-219.
   PubMedGoogle Scholar
• PATEL A, BARZI F, JAMROZIK K et al.: Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation (2004) 110:2678-2686.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of CAD in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl. J. Med. (1999) 341:410-418.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. (2002) 162:2597-2604.
   PubMed Web of Science ®Google Scholar
• CHAPMAN MJ, ASSMANN G, FRUCHART JC, SHEPHERD J, SIRTORI C; EUROPEAN CONSENSUS PANEL ON HDL-C: Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid. Curr. Med. Res. Opin. (2004) 20:1253-1268.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203-207
   PubMed Web of Science ®Google Scholar
• BROUSSEAU ME, SCHAEFER EJ, WOLFE ML et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl. J. Med. (2004) 350:1505-1515.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• LIP GY, BARNETT AH, BRADBURY A et al.: Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. J. Hum. Hypertens. (2007) 21(3):183-211.
   PubMed Web of Science ®Google Scholar